SG11201408434QA - Targeted rna-seq methods and materials for the diagnosis of prostate cancer - Google Patents
Targeted rna-seq methods and materials for the diagnosis of prostate cancerInfo
- Publication number
- SG11201408434QA SG11201408434QA SG11201408434QA SG11201408434QA SG11201408434QA SG 11201408434Q A SG11201408434Q A SG 11201408434QA SG 11201408434Q A SG11201408434Q A SG 11201408434QA SG 11201408434Q A SG11201408434Q A SG 11201408434QA SG 11201408434Q A SG11201408434Q A SG 11201408434QA
- Authority
- SG
- Singapore
- Prior art keywords
- rna
- international
- prostate cancer
- seq
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 3 January 2014 (03.01.2014) WIPOIPCT (10) International Publication Number WO 2014/003580 A1 (51) International Patent Classification: C12Q 1/68 (2006.01) C12N15/11 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/NZ2013/000114 28 June 2013 (28.06.2013) English English (30) Priority Data: 61/665,849 61/691,743 61/709,517 28 June 2012 (28.06.2012) US 21 August 2012 (21.08.2012) US 4 October 2012 (04.10.2012) US (71) Applicant: CALDERA HEALTH LTD [NZ/NZ]; PO Box 11664, Ellerslie, Auckland, 1542 (NZ). (72) Inventors: WATSON, James Douglas; Appartment 3, 18 Eltham Road, Kohimarama, Auckland, 1071 (NZ). ELTON, Clare; 17a Jacaranda Avenue, Beach Haven, Auckland, 0626 (NZ). MUSGRAVE, David Rex; 48a Queenswood Avenue, Hamilton, 3210 (NZ). (74) Agent: CALVERT, Jane; In-Legal Limited, PO Box 8026, The Terrace, Wellington, 6143 (NZ). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a)) (54) Title: TARGETED RNA-SEQ METHODS AND MATERIALS FOR THE DIAGNOSIS OF PROSTATE CANCER Figure 1: Four novel adaptations to the RNA-seq technology o 00 m o o o CJ o & cONA then purified (to is adapters and primers), or and cDNA is amplified with adaptor primers if necessary) cONA purified, and size selected if necessary cDNA library sequenced (57) Abstract: Methods for diagnosing the presence of a disorder, such as prostate cancer, in a subject are provided, such methods including detecting the relative frequency of expression of RNA biomarkers in biological a sample obtained from the subject using RNA-Seq technology and comparing the relative levels of expression with predetermined threshold levels. Levels of expression of at least two of the RNA biomarkers that are above the predetermined threshold levels are indicative of the presence of prostate cancer in the subject. The methods involve the use of at least one gene-specific primer in at least one point of the RNA-Seq protocol for tar geted sequencing of relevant transcripts.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261665849P | 2012-06-28 | 2012-06-28 | |
US201261691743P | 2012-08-21 | 2012-08-21 | |
US201261709517P | 2012-10-04 | 2012-10-04 | |
PCT/NZ2013/000114 WO2014003580A1 (en) | 2012-06-28 | 2013-06-28 | Targeted rna-seq methods and materials for the diagnosis of prostate cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201408434QA true SG11201408434QA (en) | 2015-01-29 |
Family
ID=49778731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201408434QA SG11201408434QA (en) | 2012-06-28 | 2013-06-28 | Targeted rna-seq methods and materials for the diagnosis of prostate cancer |
Country Status (9)
Country | Link |
---|---|
US (1) | US20140005058A1 (en) |
EP (1) | EP2867376B1 (en) |
JP (1) | JP2015522277A (en) |
CN (1) | CN104781415A (en) |
AU (1) | AU2013281355B2 (en) |
CA (1) | CA2877864C (en) |
NZ (1) | NZ629538A (en) |
SG (1) | SG11201408434QA (en) |
WO (1) | WO2014003580A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150252425A1 (en) * | 2014-03-05 | 2015-09-10 | Caldera Health Ltd. | Gene expression profiling for the diagnosis of prostate cancer |
EP3212793B1 (en) * | 2014-11-02 | 2020-01-08 | Arcturus Therapeutics, Inc. | Messenger una molecules and uses thereof |
KR20170116009A (en) * | 2014-12-01 | 2017-10-18 | 프라운호퍼-게젤샤프트 추어 푀르더룽 데어 안게반텐 포르슝 에.파우. | Novel rna-biomarker signature for diagnosis of prostate cancer |
ES2874275T3 (en) * | 2016-02-25 | 2021-11-04 | Hoffmann La Roche | Elimination of primer-primer interactions during primer extension |
CN105734159B (en) * | 2016-04-29 | 2019-04-05 | 北京泱深生物信息技术有限公司 | The molecular marked compound of esophageal squamous cell carcinoma |
CN108624691A (en) * | 2018-06-22 | 2018-10-09 | 杭州西合精准医疗科技有限公司 | A kind of marker and its application for judging prostatic disorders |
CN108913763A (en) * | 2018-07-03 | 2018-11-30 | 张罗 | Detect the method and application of SAA2 gene expression amount in nasal cavity cast-off cells |
CN108913765A (en) * | 2018-07-03 | 2018-11-30 | 张罗 | The application of kit and SAA2 gene as biomarker for detecting chronic nasosinusitis with nasal polyp hypotype |
KR102258977B1 (en) * | 2018-11-26 | 2021-06-01 | 국립암센터 | A method for screening a therapeutic agent for cancer using binding inhibitor of Cyclin-dependent kinase 1(CDK1) - Cyclin B1 |
CN110343761B (en) * | 2019-06-06 | 2023-06-27 | 宽盈医疗科技(上海)有限公司 | Marker group for prostate cancer and application thereof |
CN113299340B (en) * | 2021-06-09 | 2023-06-30 | 四川大学华西医院 | Screening method of target test drugs and target test drug screening device |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004048933A2 (en) * | 2002-11-21 | 2004-06-10 | Wyeth | Methods for diagnosing rcc and other solid tumors |
CA2432365A1 (en) * | 2003-06-30 | 2004-12-30 | Jack A. Schalken | Specific method of prostate cancer detection based on pca3, and kits therefore |
US7368548B2 (en) * | 2004-01-27 | 2008-05-06 | Compugen Ltd. | Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of prostate cancer |
WO2005084254A2 (en) * | 2004-02-27 | 2005-09-15 | Musc Foundation For Research Development | Enhanced detection of rna using a panel of truncated gene-specific primers for reverse transcription |
US7566532B1 (en) * | 2004-07-02 | 2009-07-28 | Quest Diagnostics Investments Incorporated | Methods for detecting retroviruses |
AU2007284651B2 (en) * | 2006-08-09 | 2014-03-20 | Institute For Systems Biology | Organ-specific proteins and methods of their use |
NZ577992A (en) | 2006-11-28 | 2012-09-28 | Pictor Ltd | Assay membrane and method of use thereof |
US20080274458A1 (en) * | 2007-05-01 | 2008-11-06 | Latham Gary J | Nucleic acid quantitation methods |
JP5985390B2 (en) | 2009-04-02 | 2016-09-06 | フリューダイム・コーポレイション | Multi-primer amplification method for adding barcode to target nucleic acid |
EP2419537B1 (en) * | 2009-04-13 | 2014-01-29 | Somagenics, Inc. | Methods and compositions for detection of small rnas |
EP2499262A4 (en) * | 2009-11-12 | 2015-01-07 | Esoterix Genetic Lab Llc | Copy number analysis of genetic locus |
EP2333104A1 (en) * | 2009-12-11 | 2011-06-15 | Lexogen GmbH | RNA analytics method |
JP2012000107A (en) * | 2010-05-18 | 2012-01-05 | Takeshi Zama | Diagnosis of tumor by using new small rna as biomarker |
WO2011154689A1 (en) * | 2010-06-07 | 2011-12-15 | King's College London | Methods and means for predicting or diagnosing diabetes or cardiovascular disorders based on micro rna detection |
WO2012027547A2 (en) * | 2010-08-25 | 2012-03-01 | Columbia University | Quantitative total definition of biologically active sequence elements |
WO2012040784A1 (en) * | 2010-09-30 | 2012-04-05 | Chipdx Llc | Gene marker sets and methods for classification of cancer patients |
CA2831074A1 (en) * | 2011-03-26 | 2012-10-04 | Oregon Health And Science University | Gene expression predictors of cancer prognosis |
-
2013
- 2013-06-28 CA CA2877864A patent/CA2877864C/en not_active Expired - Fee Related
- 2013-06-28 JP JP2015520101A patent/JP2015522277A/en active Pending
- 2013-06-28 WO PCT/NZ2013/000114 patent/WO2014003580A1/en active Application Filing
- 2013-06-28 AU AU2013281355A patent/AU2013281355B2/en not_active Ceased
- 2013-06-28 US US13/930,852 patent/US20140005058A1/en not_active Abandoned
- 2013-06-28 NZ NZ629538A patent/NZ629538A/en not_active IP Right Cessation
- 2013-06-28 EP EP13810495.5A patent/EP2867376B1/en not_active Not-in-force
- 2013-06-28 CN CN201380044811.5A patent/CN104781415A/en active Pending
- 2013-06-28 SG SG11201408434QA patent/SG11201408434QA/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2867376A4 (en) | 2015-10-28 |
CN104781415A (en) | 2015-07-15 |
NZ629538A (en) | 2016-10-28 |
EP2867376A1 (en) | 2015-05-06 |
CA2877864C (en) | 2019-05-14 |
WO2014003580A1 (en) | 2014-01-03 |
AU2013281355B2 (en) | 2018-04-05 |
JP2015522277A (en) | 2015-08-06 |
CA2877864A1 (en) | 2014-01-03 |
US20140005058A1 (en) | 2014-01-02 |
AU2013281355A1 (en) | 2015-01-29 |
EP2867376B1 (en) | 2017-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201408434QA (en) | Targeted rna-seq methods and materials for the diagnosis of prostate cancer | |
SG11201408385TA (en) | Methods of detecting diseases or conditions | |
SG11201408383SA (en) | Methods of detecting diseases or conditions using circulating diseased cells | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201408002TA (en) | Multi-parameter diabetes risk evaluations | |
SG11201900885VA (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201804086VA (en) | Methods and compositions for nucleic acid analysis | |
SG11201908088RA (en) | Antibodies against pd-l1 | |
SG11201408261UA (en) | Syringe | |
SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
SG11201403106SA (en) | Anti-phf-tau antibodies and their uses | |
SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
SG11201407200TA (en) | Liquid formulation | |
SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
SG11201901834WA (en) | Micrornas as biomarkers for endometriosis | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201810757YA (en) | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase | |
SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
SG11201810914VA (en) | Compositions and methods for diagnosing lung cancers using gene expression profiles | |
SG11201406787TA (en) | Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies | |
SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
SG11201408175YA (en) | Methods of predicting a reservoir fluid behavior using an equation of state |